AlumisNASDAQ: ALMS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 February 2021

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$632.17 M
-18%vs. 3y high
68%vs. sector
-vs. 3y high
-vs. sector
-19%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 36 min ago
$11.62+$0.29(+2.56%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ALMS Latest News

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
benzinga.com17 October 2024 Sentiment: POSITIVE

HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
globenewswire.com27 September 2024 Sentiment: POSITIVE

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001's potential to offer a highly differentiated and best-in-class treatment profile for people with moderate-to-severe plaque psoriasis Full 52-week Phase 2 OLE dataset expected 1H 2025; Phase 3 clinical program ongoing SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE) period of its Phase 2 STRIDE clinical trial of ESK-001.

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
seekingalpha.com16 September 2024 Sentiment: POSITIVE

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks.

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
globenewswire.com13 August 2024 Sentiment: POSITIVE

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming milestones.

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
globenewswire.com29 July 2024 Sentiment: POSITIVE

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program.

What type of business is Alumis?

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

What sector is Alumis in?

Alumis is in the Healthcare sector

What industry is Alumis in?

Alumis is in the Biotechnology industry

What country is Alumis from?

Alumis is headquartered in United States

When did Alumis go public?

Alumis initial public offering (IPO) was on 22 February 2021

What is Alumis website?

https://www.alumis.com

Is Alumis in the S&P 500?

No, Alumis is not included in the S&P 500 index

Is Alumis in the NASDAQ 100?

No, Alumis is not included in the NASDAQ 100 index

Is Alumis in the Dow Jones?

No, Alumis is not included in the Dow Jones index

When was Alumis the previous earnings report?

No data

When does Alumis earnings report?

The next expected earnings date for Alumis is 29 November 2024